Preclinical evidence reveals GLP-1 receptor agonists possess anti-inflammatory, antioxidative, and immunomodulatory properties that could benefit periodontal disease treatment. Human observational studies consistently show periodontitis patients have reduced endogenous GLP-1 levels, which increase following periodontal treatment, suggesting a bidirectional relationship between metabolic and oral health. This connection represents a fascinating convergence of metabolic medicine and dental health that could reshape treatment approaches. The anti-inflammatory mechanisms of GLP-1 agonists like semaglutide and liraglutide may address the chronic inflammatory cascade driving both periodontitis and metabolic dysfunction. However, the evidence remains preliminary—limited to animal studies and observational human data rather than controlled trials with periodontal endpoints. This represents an early-stage but biologically plausible therapeutic avenue that warrants serious investigation. Given that periodontal disease affects nearly half of adults and shares inflammatory pathways with diabetes, establishing this connection could offer dual benefits for patients already using these expensive medications for metabolic conditions.